Literature DB >> 16801355

Adverse cardiovascular effects of rofecoxib.

Steven E Nissen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801355     DOI: 10.1056/NEJMc066260

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  4 years after withdrawal of rofecoxib: where do we stand today?

Authors:  W Jaksch; C Dejaco; M Schirmer
Journal:  Rheumatol Int       Date:  2008-07-29       Impact factor: 2.631

2.  Uncertain risks of drug related harms, the precautionary principle and limitations of meta-analysis.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

3.  Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

Authors:  A Sommet; S Grolleau; H Bagheri; M Lapeyre-Mestre; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2008-05-29       Impact factor: 2.953

4.  NSAID choice: lessons from PRECISION.

Authors:  Grant W Reed; Steven E Nissen
Journal:  Aging (Albany NY)       Date:  2019-04-29       Impact factor: 5.682

5.  Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study.

Authors:  Skaistė Kasciuškevičiūtė; Gintautas Gumbrevičius; Aušra Vendzelytė; Arūnas Ščiupokas; Kęstutis Petrikonis; Edmundas Kaduševičius
Journal:  Medicina (Kaunas)       Date:  2018-05-11       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.